New targeted therapies for advanced prostate cancer
Official title: Targeted nanotherapies for the treatment of prostate cancer
Funded at Washington State University · NIH-10947329 · Data updated 2026-11-12
This study is exploring a new way to treat advanced prostate cancer using tiny particles that can deliver chemotherapy directly to cancer cells, helping to make the treatment more effective and reduce side effects, and it will test this method with a drug called Cabozantinib.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington State University NIH-funded |
| Lab location | 1 site (Pullman, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $406,520 |
| NIH project number | 1R21CA286235-01A1 |
| Project ID | NIH-10947329 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer who have limited treatment options.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not express the targeted protein may not benefit from this research.
What this research studies
This research focuses on developing innovative nanotechnology-based therapies specifically designed to treat advanced prostate cancer, which is a significant health concern for men. The approach involves creating specialized nanoplatforms that can deliver high doses of chemotherapy directly to cancer cells while minimizing side effects. By targeting a specific protein found on prostate cancer cells, the treatment aims to enhance the effectiveness of existing drugs and improve patient outcomes. The study will utilize a drug called Cabozantinib, which has shown promise in other cancers, to test this new delivery method.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with advanced prostate cancer.
How similar studies have gone: Previous research has shown promise in using targeted nanotherapies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
Washington State University
Pullman, United States Active
Researchers
- Principal investigator: Sharma, Anjali — Washington State University
- Study coordinator: Sharma, Anjali
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.